AIM ImmunoTech Inc.
NYSE · Healthcare · Biological Products, (No Diagnostic Substances) · Ocala, FL
AIM chart
What traders are saying about $AIM
Latest postsAIM ImmunoTech Inc. news
- aim immunoTech CEO Equels buys $5,068 in common stock By Investing.com
Investing.com South Africa ·
- AIM ImmunoTech Inc. (AIM) Stock Price | Live Quotes & Charts | AMEX
www.timothysykes.com ·
- Form 4 AIM ImmunoTech Inc: Thomas K. Equels (Director, CEO & President) For: 23 October
Investing.com Nigeria ·
- AIM ImmunoTech Inc. Estimates – AMEX:AIM
TradingView ·
- Aim ImmunoTech CEO Equels buys $5,093 of common stock By Investing.com
Investing.com South Africa ·
- Form 4 AIM ImmunoTech Inc: Thomas K. Equels (Director, CEO & President) For: 22 October By Investing.com
Investing.com South Africa ·
- Aim ImmunoTech CEO Equels buys $5,093 of common stock
Investing.com ·
- AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
Yahoo Finance ·
- AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
Yahoo Finance ·
- AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Yahoo Finance ·
- AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Yahoo Finance ·
- AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Yahoo Finance ·
AIM ImmunoTech Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $88,000 | $170,000 | $202,000 | $141,000 |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M |
| Diluted EPS | $-8.62 | $-30.92 | $-0.60 | $-0.40 |
| Total assets (year end) | $5.8M | $8.6M | $19.4M | $40.5M |
| Cash and equivalents (year end) | $3.0M | $1.7M | $5.4M | $27.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About AIM ImmunoTech Inc.
- Ticker
- AIM (NYSE)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Ocala, FL
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 946644
- Former names
- AIM ImmunoTech Inc., HEMISPHERX BIOPHARMA INC
Frequently asked questions
What exchange is AIM ImmunoTech Inc. listed on?
AIM ImmunoTech Inc. trades on the NYSE under the ticker symbol AIM.
What industry is AIM ImmunoTech Inc. in?
AIM ImmunoTech Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is AIM ImmunoTech Inc. headquartered?
AIM ImmunoTech Inc.'s business address on file with the SEC is in Ocala, FL.
When does AIM ImmunoTech Inc.'s fiscal year end?
AIM ImmunoTech Inc.'s fiscal year ends on December 31.
How much revenue did AIM ImmunoTech Inc. report?
AIM ImmunoTech Inc. reported $88,000 in revenue for calendar year 2025, according to its SEC filings.